Schonfeld Strategic Advisors LLC Next Cure, Inc. Transaction History
Schonfeld Strategic Advisors LLC
- $15 Billion
- Q1 2025
A detailed history of Schonfeld Strategic Advisors LLC transactions in Next Cure, Inc. stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 18,935 shares of NXTC stock, worth $9,278. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,935
Previous 21,800
13.14%
Holding current value
$9,278
Previous $16,000
43.75%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding NXTC
# of Institutions
38Shares Held
13.7MCall Options Held
1.7KPut Options Held
0-
Sofinnova Investments, Inc. Menlo Park, CA2.67MShares$1.31 Million0.09% of portfolio
-
Affinity Asset Advisors, LLC New York, NY2.3MShares$1.13 Million0.12% of portfolio
-
Citigroup Inc1.42MShares$695,4910.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA1.14MShares$559,1880.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA987KShares$483,7880.0% of portfolio
About NextCure, Inc.
- Ticker NXTC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 27,748,800
- Market Cap $13.6M
- Description
- NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...